Brook­ings pan­el of ex­perts lays out case for on­shoring man­u­fac­tur­ing

As the US and Eu­rope con­tin­ue to con­sid­er on­shoring phar­ma man­u­fac­tur­ing to shore up the in­ter­na­tion­al sup­ply chain, a pan­el of ex­perts, host­ed by the Brook­ings In­sti­tu­tion, ad­dressed how to shore up sup­plies and re­silien­cy as drug short­ages and oth­er sup­ply is­sues per­sist af­ter the pan­dem­ic’s ini­tial im­pact.

Speak­ing on lessons learned from the pan­dem­ic, Tom Bol­lyky, di­rec­tor of the Glob­al Health Pro­gram and Se­nior Fel­low for Glob­al Health, Eco­nom­ics and De­vel­op­ment at the Coun­cil on For­eign Re­la­tion, said that while there was gen­er­al suc­cess in mov­ing bil­lions of dos­es of the Covid-19 vac­cine once it be­came more wide­ly avail­able, there were still some dif­fi­cul­ties. More than two-thirds of coun­tries had ex­port re­stric­tions on es­sen­tial med­ical prod­ucts dur­ing the pan­dem­ic, Bol­lyky said.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN